Post-Termination Financial Terms (Termination by GSK at Will. If GSK terminates this Agreement in its entirety or with respect to a specific Program in accordance with Section 14.2 and CureVac elects the CureVac Continue Option and the license to the GSK Technology under Section 15.4e(ii), then, on a Product-by-Product and country-by-country basis effective from the Cut-Over Date, in consideration of the licenses granted in Section 15.4e(ii), CureVac shall pay GSK royalties as forth in Exhibit 15.4.
Appears in 2 contracts
Samples: Collaboration and License Agreement (CureVac N.V.), Collaboration and License Agreement (CureVac B.V.)
Post-Termination Financial Terms (Termination by GSK at Will. If GSK terminates this Agreement in its entirety or with respect to a specific Program in accordance with Section 14.2 and CureVac elects the CureVac Continue Option and the license to the GSK Technology under Section 15.4e(ii15.6(ii), then, on a COVID Product-by-COVID Product and country-by-country basis basis, effective from the Cut-Over Date, in consideration of the licenses granted in Section 15.4e(ii15.6(ii), CureVac shall pay GSK royalties as forth in Exhibit 15.415.6.
Appears in 1 contract
Samples: Covid Collaboration and License Agreement (CureVac N.V.)
Post-Termination Financial Terms (Termination by GSK at Will. If GSK terminates this Agreement in its entirety or with respect to a specific Program in accordance with Section 14.2 and CureVac elects the CureVac Continue Option and the license to the GSK Technology under Section 15.4e(ii15.5e(ii), then, on a Product-by-Product and country-by-country basis effective from the Cut-Over Date, in consideration of the licenses granted in Section 15.4e(ii15.5e(ii), CureVac shall pay GSK royalties as forth in Exhibit 15.415.5.
Appears in 1 contract
Post-Termination Financial Terms (Termination by GSK at Will. If GSK terminates this Agreement in its entirety or with respect to a specific Program in accordance with Section 14.2 and CureVac elects the CureVac Continue Option and the license to the GSK Technology under Section 15.4e(ii15.5(ii), then, on a COVID Product-by-COVID Product and country-by-country basis basis, effective from the Cut-Cut- Over Date, in consideration of the licenses granted in Section 15.4e(ii15.5(ii), CureVac shall pay GSK royalties as forth in Exhibit 15.415.5.
Appears in 1 contract
Post-Termination Financial Terms (Termination by GSK at Will. If GSK terminates this Agreement in its entirety or with respect to a specific Program in accordance with Section 14.2 and CureVac elects the CureVac Continue Option and the license to the GSK Technology under Section 15.4e(ii15.5(ii), then, on a COVID Product-by-COVID Product and country-by-country basis basis, effective from the Cut-Over Date, in consideration of the licenses granted in Section 15.4e(ii15.5(ii), CureVac shall pay GSK royalties as forth in Exhibit 15.415.5.
Appears in 1 contract
Samples: Covid Collaboration and License Agreement (CureVac N.V.)
Post-Termination Financial Terms (Termination by GSK at Will. If GSK terminates this Agreement in its entirety or with respect to a specific Program in accordance with Section 14.2 and CureVac elects the CureVac Continue Option and the license to the GSK Technology under Section 15.4e(ii15.5(ii), then, on a COVID Product-by-COVID Product and country-by-country basis basis, effective from the Cut-Over Date, in consideration of the licenses granted in Section 15.4e(ii15.5(ii), CureVac shall pay GSK royalties as forth in Exhibit 15.4.15.5. β
Appears in 1 contract
